CARDIOPROTECTIVE EFFECT OF TRIMETAZIDINE IN RATS WITH ESTABLISHED ALCOHOLIC CARDIOMYOPATHY IN THE ABSTINENCE PERIOD

DOI: https://doi.org/10.29296/24999490-2018-01-08

I.A. Miroshkina, E.O. Ionova, A.V. Nadorova, V.N. Stolyaruk, M.B. Vititnova, A.V. Sorokina, L.G. Kolik, A.D. Durnev, I.B. Tsorin, S.A. Kryzhanovskii Research Zakusov Institute of Pharmacology, Baltiyskaya st., 8, Moscow, 125315, Russian Federation E-mail: [email protected]

Aim of the study. To study trimetazidine cardioprotective effects on the translation model of alcoholic cardiomyopathy Materials and methods. Alcoholic cardiomyopathy was reproduced in white mongrel male rats used as the sole source of liquid 10% ethanol solution during 24 weeks. After the termination of this period, in the abstinence period, rats of the experimental group received trimetazidine (30 mg/kg/day, i/p) during 28 days, and the animals of the control group got the equivalent volume of the isotonic sodium chloride solution. The cardioprotective activity of trimetazidine was evaluated with the use of echocardiographic and morphological examinations. Results. Systematic experimental therapy with trimethazidine was shown to promote a statistically significant increase of the left ventricle ejection fraction (p
Keywords: 
alcoholic cardiomyopathy, translation model, rats, trimetazidine, pFox-inhibitors, cardioprotective effects, reverse remodeling, dilated heart failure

Список литературы: 
  1. Balakrishnan R., Allender S., Scarborough P., Webster P., Rayner M. The burden of alcohol-related ill health in the United Kingdom. J. Public Health. 2009; 31 (3): 366–73.
  2. John U., Hanke M. Tobacco- and alcohol-attributable mortality and years of potential life lost in Germany. Eur. J. Public Health. 2003; 13 (3): 275–7.
  3. Mokdad A.H, Marks J.S., Stroup D.F., Gerberding J.L. Actual causes of death in the United States, 2000. JAMA. 2004; 291 (10): 1238–45.
  4. Bohan N.A., Mandel` A.I., Maksimenko N.N., Mihaleva L.D. Smertel`nye ishody pri alkogol`noy zavisimosti. Narkologiya. 2007; 12: 37–40.
  5. [Bockhan N.A., Mandel’ A.I., Maximenko N.N., Michaleva L.D. Deaths in alcohol dependence. Narkologija. 2007; 12: 37–40 (in Russian)]
  6. Nemcov A.V. Alkogol`naya smertnost` v Rossii 1980–90-e gg. M.: Nalex, 2001.
  7. [Nemtsov A.V. Alcoholic mortality in Russia 1980–1990 yy. M.: Nalex, 2001 (in Russian)]
  8. Nemcov A.V. Alkogol`nyy uron regionov Rossii. M.: Nalex, 2003.
  9. [Nemtsov A.V. Alcoholic losses of Russia region. M.: Nalex, 2003. (in Russian)]
  10. Nikitina S.Yu., Kozeeva G.M. Sovershenstvovanie statistiki smertnosti ot alkogolizma. Voprosy statistiki. 2006; 11: 21–3.
  11. [Nikitina S.Yu., Kozeeva G.M. Improving mortality statistics from alcoholism. Voprosy statistiki. 2006: 11: 21–3 (in Russian)]
  12. Semenova V.G., Antonova O.I., Evdokushkina G.N., Gavrilova N.S. Poteri naseleniya Rossii v 2000–2008 gg., obuslovlennye alkogolem: masshtaby, struktura, tendencii. Social`nye aspekty zdorov`ya naseleniya. 2010; 2: 34–7.
  13. Semenova V.G., Antonova O.I., Evdokushkina G.N., Gavrilova N.S. The loss of the Russian population in 2000–2008 gg. caused by alcohol: the scale, structure, trends. Social'nye aspekty zdorov'ja naselenija. 2010; 2: 34–7 (in Russian)]
  14. Erohin Yu.A., Hritinin D.F. Porazhenie serdca pri hronicheskoy alkogol`noy intoksikacii. Vestnik novyh medicinskih tehnologiy. 2003; 4: 19–20.
  15. [Erokhin Yu.A., Chritin D.F. Cardiac involvement in chronic alcohol intoxication. Vestnik novyh medicinskih tehnologij. 2003; 4: 19–20 (in Russian)]
  16. Preedy V.R., Salisbury J.R., Peters T.J. Alcoholic muscle disease: features and mechanisms. J. Pathol. 1994; 173: 309–15.
  17. Wannamethee G., Shaper A.G. Alcohol and sudden cardiac death. Br. Heart J. 1992; 68 (5): 443–8.
  18. Chazov E.I. Vnezapnaya smert`. 2013. http: // www. medicusamicus. com/ index. php?action=2x1229x1.
  19. [Chazov E.I. Sudden death. 2013. http: // www. medicusamicus. com/ index. php?action=2x1229x1.].
  20. Iacovoni A., De Maria R., Gavazzi A. Alcoholic cardiomyopathy. J. Cardiovasc. Med. 2010; 11 (12): 884–92.
  21. Rehm J., Zatonski W., Taylor B., Anderson P. Epidemiology and alcohol policy in Europe. Addiction. 2011; 106 (1): 11–9.
  22. Vikhert A.M., Tsiplenkova V.G., Cherpachenko N.M. Alcoholic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 1986; 8 (Suppl. A.): 3A–11A.
  23. Permyakov A.V., Pirogov A.S., Yakimov I.A. Alkogol`naya kardiomiopatiya po dannym GUZ «BSME`» MZ UR (g. Izhevska) za 3 goda. Problemy e`kspertizy v medicine. 2003; 3 (2): 11–3.
  24. [Permyakova A.V., Pirogov A.C., Yakimov I.A. et al. Alcoholic cardiomyopsathy according GUZ «BSME» MZ UR (Izhevsk) for 3 years. Problemy jekspertizy v medicine. 2003; 3 (2): 11–3 (in Russian)]
  25. Klatsky A.L. Alcohol and cardiovascular health. Physiol. Behav. 2010; 100 (1): 76–81.
  26. Drapkina O.M., Ashihmin Ya.I., Ivashkin V.T. Problema alkogol`noy kardiomiopatii. Vrach. 2005; 8: 48–50.
  27. [Drapkina O.M., Ashikhmin Ia.I., IvashkinV.T. The problem of alcoholic cardiomyopathy. Vrach. 2005; 8: 48–50 (in Russian)]
  28. Ivashkin V.T., Drapkina O.M., Ashihmin Ya.I. Alkogol`naya kardiomiopatiya. Medicinskaya pomoshh`: Nauchno-prakticheskiy zhurnal. 2006; 3: 11–5.
  29. [Ivashkin V.T., Drapkina O.M., Ashikhmin Ia.I. Alcoholic cardiomyopathy. Medicinskaja pomoshh': Nauchno-prakticheskij zhurnal. 2006; 3: 11–5 (in Russian)]
  30. Drapkina O.M. Problema alkogol`noy kardiomiopatii. E`ffektivnaya farmakoterapiya v kardiologii i angiologii. 2008; 1: 30–4.
  31. [Drapkina O.M. The problem of alcoholic cardiomyopathy. Effective pharmacotherapy in a cardiology and angiology. 2008; 1: 30–4 (in Russian)]
  32. Ryabenko D.V., Kornienko T.M. Alkogol`naya kardiomiopatiya. Ukrains`kiy kardiologichniy zhurnal. 2010; 4: 91–7.
  33. [Ryabenko D.V., Kornyenko T.M. Alcoholic catdiomyopathy. Ukr. cardiol. J. 2010; 4: 91–7 (in Russian)]
  34. Piano M.R., Phillips Sh.A. Alcoholic cardiomyopathy: Pathophysiologic insight. Cardiovasc. Toxicol. 2014; 14 (4): 291–308.
  35. Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation toglucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyal coenzyme a tholase. Circ. Res. 2000; 86: 580–8.
  36. Gordeev I.G., Bekchiu E.A., Lyusov V.A. Ocenka vliyaniya miokardial`nyh citoprotektorv na processy perekisnogo okisleniya lipidov u bol`nyh so stabil`noy stenokardiey do i posle hirurgicheskoy revaskulyarizacii miokarda. Rossiyskiy kardiologicheskiy zhurnal. 2005; 3: 41–6.
  37. [Gordeev I.G., Bekchiu E.A., Lusov V.A. Evaluation of the influence of myocardial citoprotector on lipid peroxidation in patients with stable angina pectoris before and after surgical myocardial revascularization. Roc. Kardiol. J. 2005; 3: 41–6 (in Russian)]
  38. Kryzhanovskiy S.A., Corin I.B., Kolik L.G., Stolyaruk V.N., Vititnova M.B., Ionova E.O., Sorokina A.V., Durnev A.D., Seredenin S.B. Translyacionnaya model` alkogol`noy kardiomiopatii. Molekulyarnaya medicina. 2015; 3: 40–7.
  39. [Kryzhanovsky S.A., Tsorin I.B., Kolik L.G., Stolyaruk V.N., Vititnova M.B., Ionova E.O., Sorokina A.V., Durnev A.D., Seredenin S.B. The translation model of alcoholic cardiomyopathy. Molecular medicine. 2015; 3: 40–7 (in Russian)]
  40. Kryzhanovskiy S.A., Kolik L.G., Corin I.B., Corin I.B., Ionova E.O., Stolyaruk V.N., Vititnova M.B., Nadorova A.V., Seredenin S.B. K vozmozhnosti ispol`zovaniya e`hokardiografii dlya ocenki e`tapov formirovaniya alkogol`noy kardiomiopatii. Fiziologiya cheloveka. 2014; 40 (1): 122–8.
  41. [Kryzhanovsky S.A., Kolik L.G., Tsorin I.B., Ionova E.O., Stolyaruk V.N., Vititnova M.B., Nadorova A.V., Seredenin S.B. To the potential use of alcocholic cardiomyopathy echocardiography assessment of forming. Human Physiology. 2014; 40 (1): 122–8 (in Russian)]
  42. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., Sutton M.S., Stewart W.J.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recomendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Camber Quantification Writing Group, developed in conjunction with European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440–63.
  43. Tereshhenko S.N., Zhirov I.V., Kotaeva E.A., Malichenko E.V. Alkogol`naya i dilatacionnaya kardiomiopatiya. Pravomochen li znak ravenstva? Kardiologiya. 2008; 3: 93–6.
  44. [Teresshenko V.G., Zhirov I.V., Kataeva E.A., Malichenko E.V. Alcoholic and dilated cardiomyopathy. Empowered to whether the sign of equality? Kardiologiia; 2008; 3: 93–6 (in Russian)]
  45. Fernandez-Sola J., Nicolbs J.M., Pary J.C., Sacanella E., Fatju F., Cofbn M., Estruch R. Diastolic function impairment in alcoholics. Alcohol. Clin. Exp. Res. 2000; 24 (12): 1830–5.
  46. Guzzo-Merello G., Domingues F., Gonzalez-Lopez E. et al. Malinant ventricular arrhythmias in alcoholic cardiomyopathy. 2015; 199: 99–105.
  47. Bogza M.V., Sorokina V.V., Konev V.P., Goloshubina V.V. Morfofunkcional`nye paralleli pri alkogol`noy kardiomiopatii v aspekte vnezapnoy smerti. Izvestiya vysshih uchebnyh zavedeniy. Povolzhskiy region. Medicinskie nauki. 2011; 2 (8): 19–24.
  48. [Bogza M.V., Sorokina V.V., Konev V.P., Golochubina V.V. Morphological and functional parallels with alcoholic cardiomyopathy in terms of sudden death. Izvestija vysshih uchebnyh zavedenij. Povolzhskij region. Medicinskie nauki. 2011; 2 (8): 19–24 (in Russian)]
  49. Panchenko L.F., Moiseev V.S., Pirozhkov S.V. i soavt. Soderzhanie markerov vospaleniya i citokinov v krovi bol`nyh alkogol`noy kardiomiopatiey i ishemicheskoy bolezn`yu serdca na raznyh stadiyah serdechnoy nedostatochnosti. Kardiologiya. 2016; 55 (3): 41–8.
  50. [PanchenkoL.F., MoiseevV.S., Pirozhkov S.V. et al. Blood content of markers of inflammation and cytokines in patients with alcoholic cardiomyopathy and ischemic heart disease at various stages of heart failure. Kardiologia. 2015; 55 (3): 41–8 (in Russian)]
  51. Radu R.I., Bold A., Pop O.T. et al. Histological and immunohistol\chemical changes of the myocardium in dilated cardiomyopathy. Rom. J. Morphol. Embriol. 2012; 53 (2): 269–75.
  52. Lankin V.Z., Tihadze A.K., Belenkov Yu.N. Svobodnoradikal`nye processy pri zabolevaniyah serdechno-sosudistoy sistemy. Kardiologiya. 2000; 40 (7): 48–61.
  53. [Lankin V.Z., Tihadse A.K., Belenkov Yu.N. Free-radical processes at the diseases of the cardiovascular system. Kardiology. 2000; 40 (7): 48–61 (in Russian)]
  54. Ho E., Karimi Galougashi K., Liu C.C. et al. Biological markers of oxidative stress: Applications to cardiovascular research and practice Redox Biology. 2013; 13: 483–91.
  55. Daille-Donne I., Rossi R., Colombo R. et al. Biomarkers of oxidative damage in human disease. Clinical Chemistry. 2006; 52 (4): 601–23.
  56. Vasil`ev S.V., Maychuk E.Yu., Vasil`ev V.Yu. Membranosohranyayushhee deystvie trimetazidina u bol`nyh ostrym infarktom miokarda. Ros. kardiol. zh. 2014; 12: 80–4.
  57. [Vasil’ev S.V., Maychuk E.Yu., Vasil’ev V.Yu. Membranosohranausee effect of trimetazidine in patients with acute myocardial infarction. Roc. Kardiol. J. 2014; 12: 80–4 (in Russian)]
  58. Tabbi-Anneni I., Helies-Toussant C., Morin D. et al. Preventation of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover? J. Pharmacol. And Exp. Ther. 2003; 304 (3): 1003–9.
  59. Tuunanen H., Engblom E., Naum A. et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation, 2008; 118: 1250–8.
  60. Von Hehling S., Jankowska E.A., Anker S.D. Tumor necrosis factor-alpha and the failing heart: pathophysiology and therapeutic implication. Basic Res. Cardiol. 2004; 99: 1479–86.
  61. Bozkurt B., Kribbs S.B., Clubb F.J. et al. Pathophysiologically relevant concentration of tumor necrosis factor-alpha promote progressive dysfunction and remodeling in rats. Circulation. 1998; 97: 1382–91.
  62. Melendez G.C., McLarty J.L., Levick S.P. et al. Interleukin-6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010; 56: 225–31.
  63. Napoli P.Di., Toccardi A.A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients wih ischaemic dilated cardiomyopathy. Heart. 2005; 91: 161–5.